CytoSorbents Revenue and Competitors

Claim your profile

Monmouth Junction, NJ USA

Location

#5354

Growjo Ranking

Estimated Revenue & Valuation

  • CytoSorbents's estimated annual revenue is currently $53.2M per year.(i)
  • CytoSorbents received $15.0M in venture funding in April 2018.
  • CytoSorbents's estimated revenue per employee is $251,000
  • CytoSorbents's total funding is $22.6M.

Employee Data

  • CytoSorbents has 212 Employees.(i)
  • CytoSorbents grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.8M7N/AN/AN/A
#2
$257M10242%N/AN/A
#3
$11.5M46-12%N/AN/A
#4
$403.6M1608-4%N/AN/A
#5
$8.5M34-3%N/AN/A
#6
$3M120%N/AN/A
#7
$11M44-2%N/AN/A
#8
$20.6M82-8%N/AN/A
#9
$1455.5M57995%N/AN/A
#10
N/A1160%$29.1MN/A

CytoSorbents (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.com

keywords:Fitness and Wellness,Healthcare,Pharmaceuticals,Physical Security,Security

$22.6M

Total Funding

212

Number of Employees

$53.2M

Revenue (est)

20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CytoSorbents News

2022-04-17 - CytoSorbents to Report First Quarter 2022 Operating and Financial Results

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...

2022-04-13 - CytoSorbents To Expand Direct Sales of CytoSorb® to the ...

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...

2022-03-30 - CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$36M22618%N/A
#2
N/A2767%N/A
#3
$76.4M380-1%$125M
#4
$129.8M5774%N/A

CytoSorbents Funding

DateAmountRoundLead InvestorsReference
2013-10-21$0.7MUndisclosedArticle
2014-03-10$10.2MUndiclosedBrean Capital LLCArticle
2015-01-15$9.5MUndisclosedBrean Capital, LLCArticle
2015-01-26$0.4MUndisclosedTechnology Business Tax Certificate Transfer ProgramArticle
2016-02-02$325.0MUndisclosedNJEDAArticle
2016-07-05$10.0MUndisclosedBridge BankArticle
2016-12-13$0.3MUndisclosedArticle
2017-04-03$11.5MUndisclosedCowen and CompanyArticle
2017-07-06$5.0MUndisclosedLife Sciences Group of Bridge BankArticle
2018-04-05$15.0MUndisclosedBridge BankArticle